FastWave: The Next Generation of Intravascular Lithotripsy (IVL)
Led by proven medtech entrepreneurs, we’re developing two differentiated IVL energy systems to advance the treatment of calcific disease.
Lethal but Treatable: Coronary Artery Disease (CAD)
and Peripheral Artery Disease (PAD)
1 in 4 deaths in the U.S.
is caused by CAD.¹
Every year, CAD causes 17.8 million deaths globally.¹
A limb is amputated every
3-5 minutes in the U.S.²
1 in 2 patients die from
amputation within 1 year.³
Lethal but Treatable: Coronary Artery Disease (CAD)
and Peripheral Artery Disease (PAD)
1 in 4 deaths in the U.S.
is caused by CAD.¹
Every year, CAD causes 17.8 million deaths globally.¹
A limb is amputated every
3-5 minutes in the U.S.²
1 in 2 patients die from
amputation within 1 year.³
Calcium is Highly Prevalent in CAD and PAD
Calcium is Highly Prevalent in CAD and PAD
Calcific plaque, which is prevalent in about 30% of CAD patients⁴, resists vessel expansion, making it difficult to treat with today’s interventional modalities.
Calcific plaque, which is prevalent in about 30% of CAD patients⁴, resists vessel expansion, making it difficult to treat with today’s interventional modalities.
"We continue to encounter coronary and peripheral disease complicated by severe calcium."
Dr. Amir Kaki
Interventional Cardiologist
"Calcium poses significant therapeutic challenges in treating peripheral artery disease."
Dr. Venkatesh Ramaiah
Vascular Surgeron
Calcium is Highly Prevalent in CAD and PAD
Calcific plaque, which is prevalent in about 30% of CAD patients⁴, resists vessel expansion, making it difficult to treat with today’s interventional modalities.
"We continue to encounter coronary and peripheral disease complicated by severe calcium."
Dr. Amir Kaki
Interventional Cardiologist
"Calcium poses significant therapeutic challenges in treating peripheral artery disease."
Dr. Venkatesh Ramaiah
Vascular Surgeron
IVL Has Been Rapidly Adopted for Calcific Disease Treatment
The utilization of IVL for percutaneous coronary interventions is expected to grow at a 49% annual compounded rate due to its ease of use, favorable safety profile, and exceptional therapeutic efficacy.⁵
IVL Has Been Rapidly Adopted for Calcific Disease Treatment
The utilization of IVL for percutaneous coronary interventions is expected to grow at a 49% annual compounded rate due to its ease of use, favorable safety profile, and exceptional therapeutic efficacy.⁵
FastWave is Empowering Physicians with Advanced IVL Technology
FastWave is Empowering Physicians with Advanced IVL Technology
Our focus is clear: build upon the established success of IVL technology to enable interventionalists to deliver improved treatments and better outcomes for their patients.
Our focus is clear: build upon the established success of IVL technology to enable interventionalists to deliver improved treatments and better outcomes for their patients.
Advantages of Artero™ Electric IVL
Smarter Usability
One click activation, no reusable cables, no recharging – intuitive plug and play console with real time feedback.
More Durable Emitter Design
Individually powered electrodes resist degradation and deliver pulses for 2x faster, for more efficient therapy.
Advanced Balloon Design
Coextruded, dual layer balloons with hydrophilic coating improve crossability and rupture resistance.
Circumferential Pressure Coverage
Uniform energy distribution allows for broader treatment of arterial calcium.
Advantages of Sola™ Laser IVL
Sleek, Single Emitter Profile
Improves crossability and deliverability in tight, calcified vessels.
High Speed Energy Delivery (5 Hz)
5x faster pulse rate increases procedural efficiency and shortens ischemic time in vulnerable patients.
Maximum Pulses per Catheter
Translational emitter design resists degradation for continuous therapy of diffuse calcium.
Pulse to Pulse 360° Sonic Output
Delivers circumferential energy with every pulse for optimal calcium fracture.
FastWave is Empowering Physicians with Advanced IVL Technology
Our focus is clear: build upon the established success of IVL technology to enable interventionalists to deliver improved treatments and better outcomes for their patients.
Advantages of Artero™ Electric IVL
Smarter Usability
One click activation, no reusable cables, no recharging – intuitive plug and play console with real time feedback.
More Durable Emitter Design
Individually powered electrodes resist degradation and deliver pulses for 2x faster, for more efficient therapy.
Advanced Balloon Design
Coextruded, dual layer balloons with hydrophilic coating improve crossability and rupture resistance.
Circumferential Pressure Coverage
Uniform energy distribution allows for broader treatment of arterial calcium.
Advantages of
Sola™ Laser IVL
Sleek, Single Emitter Profile
Improves crossability and deliverability in tight, calcified vessels.
High Speed Energy Delivery (5 Hz)
5x faster pulse rate increases procedural efficiency and shortens ischemic time in vulnerable patients.
Maximum Pulses per Catheter
Translational emitter design resists degradation for continuous therapy of diffuse calcium.
Pulse to Pulse 360° Sonic Output
Delivers circumferential energy with every pulse for optimal calcium fracture.
Successful First-in-Human (FIH) Studies
Successful First-in-Human (FIH) Studies
FastWave’s next-generation IVL platforms are showing promising early results. In first-in-human studies, both the Sola™ L-IVL and Artero™ E-IVL systems achieved 100% procedural success and no in-hospital complications, each meeting its primary endpoint.
FastWave’s next-generation IVL platforms are showing promising early results. In first-in-human studies, both the Sola™ L-IVL and Artero™ E-IVL systems achieved 100% procedural success and no in-hospital complications, each meeting its primary endpoint.
Peripheral FIH Study
In our FIH peripheral study, the Artero™ E-IVL system was used to successfully treat nine limbs with 100% lesions crossed, with a mean residual diameter stenosis of only 5.9%. This was a 93% reduction from baseline, indicating an almost complete resolution of blockages.
9 successfully treated limbs across 8 patients
100% of lesions crossed, including 3 CTOs
Post-treatment mean residual diameter stenosis of 5.9%
0% AEs with no balloon ruptures
9 successfully treated patients with complex calcified coronary lesions
100% stent delivery success
0 in-hospital MACE or adverse events at 30 days
Calcium fracture confirmed via IVUS in 100% of cases
Coronary FIH Study
In our FIH coronary study, treatment with the Sola™ L-IVL system achieved 100% stent delivery success and no in-hospital complications across the first nine patients. The procedure reduced arterial blockages on average from 57.1% to just 8.6%, representing an 85% improvement.
Successful First-in-Human (FIH) Studies
FastWave’s next-generation IVL platforms are showing promising early results. In first-in-human studies, both the Sola™ L-IVL and Artero™ E-IVL systems achieved 100% procedural success and no in-hospital complications, each meeting its primary endpoint.
Peripheral FIH Study
In our FIH peripheral study, the Artero™ E-IVL system was used to successfully treat nine limbs with 100% lesions crossed, with a mean residual diameter stenosis of only 5.9%. This was a 93% reduction from baseline, indicating an almost complete resolution of blockages.
9 successfully treated limbs across 8 patients
100% of lesions crossed, including 3 CTOs
Post-treatment mean residual diameter stenosis of 5.9%
0% AEs with no balloon ruptures
9 successfully treated patients with complex calcified coronary lesions
100% stent delivery success
0 in-hospital MACE or adverse events at 30 days
Calcium fracture confirmed via IVUS in 100% of cases
Coronary FIH Study
In our FIH coronary study, treatment with the Sola™ L-IVL system achieved 100% stent delivery success and no in-hospital complications across the first nine patients. The procedure reduced arterial blockages on average from 57.1% to just 8.6%, representing an 85% improvement.
FastWave is Advancing at an
Unparalleled Pace
February 2021
FastWave established as a stand-alone Delaware C-corp.
August 2021
FastWave raises $12M Series A round of financing.
November 2022
USPTO grants FastWave its first utility patent within 6 months of filing.
April 2023
USPTO grants FastWave its second IVL utility patent.
June 2023
FastWave closes oversubscribed private financing round within a few weeks.
January 2024
FastWave completes enrollment for the first-in-human study of its peripheral IVL system.
March, April, and May 2024
USPTO grants FastWave its third, fourth, and fifth IVL utility patents.
June 2024
FastWave closes oversubscribed $19M financing round in less than a month.
December 2024
USPTO grants FastWave its sixth IVL utility patent.
January 2025
USPTO grants FastWave its seventh IVL utility patent.
May 2025
FastWave commences FIH coronary feasibility study with its L-IVL system.
July 2025
USPTO grants FastWave its eighth IVL utility patent.
November 2025
FastWave completes enrollment for 30-patient L-IVL feasibility study; USPTO grants FastWave its ninth utility patent.
FastWave is Advancing at an
Unparalleled Pace
February 2021
FastWave established as a stand-alone Delaware C-corp.
August 2021
FastWave raises $12M Series A round of financing.
November 2022
USPTO grants FastWave its first utility patent within 6 months of filing.
April 2023
USPTO grants FastWave its second IVL utility patent.
June 2023
FastWave closes oversubscribed private financing round within a few weeks.
January 2024
FastWave completes enrollment for the first-in-human study of its peripheral IVL system.
March, April, and May 2024
USPTO grants FastWave its third, fourth, and fifth IVL utility patents.
June 2024
FastWave closes oversubscribed $19M financing round in less than a month.
December 2024
USPTO grants FastWave its sixth IVL utility patent.
January 2025
USPTO grants FastWave its seventh IVL utility patent.
May 2025
FastWave commences FIH coronary feasibility study with its L-IVL system.
July 2025
USPTO grants FastWave its eighth IVL utility patent.
November 2025
FastWave completes enrollment for 30-patient L-IVL feasibility study; USPTO grants FastWave its ninth utility patent.
Invest in the Future of IVL
We oversubscribed our last round of financing in just a few weeks, so don’t miss out on the next opportunity to invest.
$50M+ raised from corporate venture, VC, and KOLs.
Successful peripheral and coronary FIH procedures.
Only market incumbent acquired in 2024 by J&J for $13B.
9 patents granted by the USPTO and multiple FTOs.
Invest in the Future of IVL
We oversubscribed our last round of financing in just a few weeks, so don’t miss out on the next opportunity to invest.
$50M+ raised from corporate venture, VC, and KOLs.
Successful peripheral and coronary FIH procedures.
Only market incumbent acquired in 2024 by J&J for $13B.
9 patents granted by the USPTO and multiple FTOs.
Invest in the Future of IVL
We oversubscribed our last round of financing in just a few weeks, so don’t miss out on the next opportunity to invest.
$50M+ raised from corporate venture, VC, and KOLs.
Successful peripheral and coronary FIH procedures.
Only market incumbent acquired in 2024 by J&J for $13B.
9 patents granted by the USPTO and multiple FTOs.
Invest in the Future of IVL
We oversubscribed our last round of financing in just a few weeks, so don’t miss out on the next opportunity to invest.
$50M+ raised from corporate venture, VC, and KOLs.
Successful peripheral and coronary FIH procedures.
Only market incumbent acquired in 2024 by J&J for $13B.
9 patents granted by the USPTO and multiple FTOs.
Follow FastWave's Journey
Next-level intravascular lithotripsy (IVL) devices for calcific artery disease.
© 2026 FastWave Medical Inc.
FastWave Medical is developing devices limited by Federal (or United States) law to investigational use. To see FastWave’s patents, click here.
¹ Source: https://pubmed.ncbi.nlm.nih.gov/32119297
Follow FastWave's Journey
Next-level intravascular lithotripsy (IVL) devices for calcific artery disease.
© 2026 FastWave Medical Inc.
FastWave Medical is developing devices limited by Federal (or United States) law to investigational use. To see FastWave’s patents, click here.
¹ Source: https://pubmed.ncbi.nlm.nih.gov/32119297
Follow FastWave's Journey
Next-level intravascular lithotripsy (IVL) devices for calcific artery disease.
© 2026 FastWave Medical Inc.
FastWave Medical is developing devices limited by Federal (or United States) law to investigational use. To see FastWave’s patents, click here.
¹ Source: https://pubmed.ncbi.nlm.nih.gov/32119297
Follow FastWave's Journey
Next-level intravascular lithotripsy (IVL) devices for calcific artery disease.
© 2026 FastWave Medical Inc.
FastWave Medical is developing devices limited by Federal (or United States) law to investigational use. To see FastWave’s patents, click here.
¹ Source: https://pubmed.ncbi.nlm.nih.gov/32119297